{"prompt": "['All screening evaluations must be completed and reviewed to confirm that patients meet all', 'eligibility criteria before enrolment. The investigator will maintain a screening log to record', 'details of all patients screened and to confirm eligibility or record reasons for screening', 'failure, as applicable.', '4.5.2', 'Medical History, Concomitant Medication, and Demographic Data', 'Medical history will be recorded at baseline and will include: clinically significant diseases', 'within the past five years, surgeries, breast and other cancer history (including prior cancer', 'therapies and procedures), complete cardiovascular history, cardiac risk factors, and', 'reproductive status. In addition, all medications (e.g., prescription drugs, over-the-counter', 'drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by the', 'patient within seven days prior to initiation of study treatment will be recorded.', 'Demographic data collected will include age, sex, and self-reported race / ethnicity.', '4.5.3', 'Pathology', 'Pathology reports from the initial breast cancer diagnosis and from breast cancer surgery will', 'be collected prior to randomization. The report from breast surgery will be used to determine', 'pathological response status for randomization stratification.', 'Results of HER2 and hormone receptor testing conducted by a local laboratory based on', 'breast tumour tissue obtained prior to initiation of neoadjuvant treatment will be collected to', 'assure study eligibility (HER2) and for randomization stratification (hormone receptor status).', '4.5.4', 'Physical Examinations', 'A complete physical examination, performed during Screening and other specified visits,', 'should include physical measurements (body weight in kilograms and, at screening only,', 'height in centimetres) and evaluation of the head; eyes; ears; nose; throat; and the', 'cardiovascular, dermatologic, musculoskeletal, respiratory, gastrointestinal, genitourinary,', 'and neurologic systems. Any abnormality identified at baseline should be recorded on the', 'General Medical History and Baseline Conditions eCRF.', 'Limited, symptom-directed physical examinations including weight, should be performed at', 'specified post-baseline visits and as clinically indicated. New or worsened clinically', 'significant abnormalities should be recorded as AEs on the Adverse Event eCRF.', 'During the study Follow-up Period, physical examinations should be completed per', 'institutional practice or the ACS / ASCO Breast Cancer Survivorship Care Guideline', '[Runowicz et al. 2016, see Appendix 4].', '4.5.5', 'Vital Signs', 'Vital signs will include temperature and, with the patient in a seated position, heart rate,', 'respiration rate, and systolic and diastolic blood pressure.', '4.5.6', 'ECOG Performance status', 'Performance status will be assessed according to ECOG definitions provided in Appendix 5.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '51 / Protocol MO40628, Version 12']['4.5.7', 'Clinical Breast Examination', 'Clinical breast examinations must be performed prior to study entry to assess post-surgery', 'wound healing, eligibility for adjuvant treatment initiation, and to detect residual / recurrent', 'disease. During the study treatment periods clinical breast examinations must be conducted', 'to detect signs of locoregional relapse during the study treatment periods. The examination', 'should be conducted per institutional practice and include examination of the breast, axilla,', 'and supraclavicular fossa. If the patient shows disease progression post-baseline, this', 'should be recorded on the Disease Status eCRF.', 'During the study Follow-up Period, assessments should be completed per institutional', 'practice or the ACS / ASCO Breast Cancer Survivorship Care Guideline [Runowicz et al.', '2016, see Appendix 4].', '4.5.8', 'Mammograms', 'Mammograms conducted at the time of diagnosis (before initiation of the neoadjuvant', 'treatment) as well as pre-surgery (if performed) will be collected. Mammograms collected', 'and/or conducted for the study (including pre-neoadjuvant treatment, pre-surgery, and', 'Follow-up Period evaluations) can be replaced by another conventional imaging method', 'such as magnetic resonance imaging (MRI) or ultrasound per institutional practice, at the', \"investigator's discretion, but the same method of assessment must be used for each\", 'evaluation for an individual patient. If a mammogram (or acceptable alternative breast', 'imaging evaluation) has been conducted as part of routine care within four months prior to', 'the End of Treatment Visit, it may be used in lieu of the End of Treatment Visit evaluation.', '4.5.9', 'Diagnosis of Breast Cancer Recurrence or Second Primary Cancer', 'All patients must be followed to assess disease recurrence and second primary cancers.', 'The designation of disease recurrence whether local, regional or distant, or a diagnosis of', 'second primary cancer will be conducted per institutional practice or according to ACS /', 'ASCO Breast Cancer Survivorship Care Guideline [Runowicz et al. 2016; see Appendix 4]', 'but can be made only when clinical, laboratory, radiological and/or histological findings', 'support the diagnosis.', 'The diagnosis of a breast cancer progression, recurrence or a second primary tumour', 'should be confirmed histologically whenever clinically possible. The earliest date of', 'diagnosis of recurrent disease should be used and recorded. This date should be based on', 'objective clinical, radiological, histological, or cytological evidence. The date of disease', 'recurrence should be reported as the date of first diagnosis of a lesion (i.e. an objective', 'finding), not the date of occurrence of the first symptom.', 'Recurrent disease includes local, regional, and distant recurrence and contralateral invasive', 'breast cancer. Patients who are diagnosed with in situ breast disease or second (non-', 'breast) malignancies should be maintained in regular follow-up wherever possible to fully', 'capture any subsequent recurrent breast cancer events. In cases of diagnostic doubt (e.g. ill-', 'defined, palpable mass in an irradiated breast), histologic or cytologic confirmation of', 'recurrence should be obtained whenever possible.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '52 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}